Skip to main content
Clinical Trials/ACTRN12609001045202
ACTRN12609001045202
Recruiting
Phase 2

An evaluation of the safety and efficacy of intracoronary selected CD 133+ bone marrow stem cells in cardiac recovery after acute myocardial infarct and left ventricular dysfunction: COMPARE-AMI a randomized controlled double blind clinical study

Miltenyi Biotech Inc.0 sites40 target enrollmentDecember 8, 2009

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Miltenyi Biotech Inc.
Enrollment
40
Status
Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 8, 2009
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Miltenyi Biotech Inc.

Eligibility Criteria

Inclusion Criteria

  • acute ST\-elevation myocardial infarct successfully reperfused by means of coronary stent implantation and demonstrated a substantial persistent LV dysfunction defined by a LVEF \<50% but \>25% on echocardiography obtained within 48 hours after the successful reperfusion therapy.

Exclusion Criteria

  • known previous myocardial infarct, cardiogenic shock, chronic cardiomyopathy, liver disease, renal failure, concomitant disease with a life expectancy of less than 1 year, alcohol or drug dependency, contraindication for bone marrow (BM) aspiration, blood transfusion in the previous 24 hours, hematopoietic disease, chronic inflammatory disease, malignancy, stroke in the previous 3 months or transient ischemic attack in the previous 24 hours.

Outcomes

Primary Outcomes

Not specified

Similar Trials